2',4-Dihydroxychalcone |
Catalog No.GC78944
One-Click Copy Product Info
|
2',4-Dihydroxychalcone is an orally active natural chalcone flavonoid.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 13323-66-5
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
2',4-Dihydroxychalcone is an orally active natural chalcone flavonoid. 2',4-Dihydroxychalcone restores intestinal barrier integrity by upregulating tight junction proteins, regulates intestinal flora balance and alleviates inflammation. 2',4-Dihydroxychalcone induces GPX4 degradation, ferroptosis and apoptosis, triggers cell cycle arrest, and exhibits broad anti-tumor activity. 2',4-Dihydroxychalcone also possesses antifungal activity, antileishmanial activity, and reduces the hemolytic effect and virulence of Vibrio vulnificus [1] [2] [3] [4] [5] [6].
In Vivo, 2',4-Dihydroxychalcone (10-30 mg/kg; i.g.; daily; 10 days) significantly alleviates DSS -induced acute ulcerative colitis in C57BL/6J mice by inhibiting NLRP3 inflammasome activation, restoring gut barrier integrity, and balancing gut microbiota, with no observed organ toxicity[1]. 2',4-Dihydroxychalcone (6.25-12.5 mg/kg; i.p.; repeated dosing schedule) significantly inhibits cholangiocarcinoma xenograft tumor growth with minimal organ toxicity[2]. 2',4-Dihydroxychalcone (15 mg/kg; injection; single dose) provides ~50% protection to Galleria mellonella larvae against Vibrio vulnificus infection[6].
In Vitro, 2',4-Dihydroxychalcone (1.25-40 μM; 1-2 h) selectively inhibits NLRP3 inflammasome activation in THP-1-derived macrophages and 774A.1 macrophages by blocking the cleavage of caspase-1 and Gasdermin D, and exhibits no cytotoxicity at concentrations up to 40 μM[1]. 2',4-Dihydroxychalcone (25 μM; 1 h) potently inhibits Nigericin -induced IL-1β secretion in THP-1-derived macrophages[1]. 2',4-Dihydroxychalcone (12.5-50 µM; 24-72 h) potently inhibits the proliferation of HuCCT1 and QBC939 cholangiocarcinoma cells in a concentration-dependent manner[2]. 2',4-Dihydroxychalcone (12.5-50 µM; 14 days) inhibits the colony-forming ability of HuCCT1 and QBC939 cholangiocarcinoma cells in a concentration-dependent manner[2]. 2',4-Dihydroxychalcone (25 µM; 24 h) inhibits the proliferation of HuCCT1 and QBC939 cholangiocarcinoma cells by reducing EdU incorporation[2]. 2',4-Dihydroxychalcone (12.5-50 µM; 48 h) inhibits horizontal and vertical migration of HuCCT1 and QBC939 cholangiocarcinoma cells in a concentration-dependent manner[2]. 2',4-Dihydroxychalcone (12.5-50 µM; 24 h) increases intracellular ROS levels in HuCCT1 and QBC939 cholangiocarcinoma cells in a concentration-dependent manner[2]. 2',4-Dihydroxychalcone (12.5-50 µM; 24 h) induces ferroptosis in HuCCT1 and QBC939 cholangiocarcinoma cells[2]. 2',4-Dihydroxychalcone (12.5-50 µM; 24 h) inhibits epithelial-mesenchymal transition in HuCCT1 and QBC939 cholangiocarcinoma cells, while downregulating the PI3K/AKT/mTOR signaling pathway and ferroptosis-related markers SLC7A11 and GPX4[2]. 2',4-Dihydroxychalcone (12.5-50 µM) downregulates the expression of ERO1A in HuCCT1 and QBC939 cholangiocarcinoma cells in a concentration-dependent manner[2]. 2',4-Dihydroxychalcone (0.06-256 μg/mL; 48 h) inhibits the metabolic activity and hyphal growth of Aspergillus fumigatus Af293, with an MIC50 ranging from 64 to 128 μg/mL, and significantly reduces hyphal growth at a concentration of 256 μg/mL[3]. 2',4-Dihydroxychalcone (8 μg/mL; 48 h) inhibits the radial growth of Aspergillus fumigatus Af293 by 20%, blocks its sporulation process, and reduces the expression levels of sporulation-related genes brlA, abaA and wetA by 3-5 folds[3]. 2',4-Dihydroxychalcone (8 μg/mL; 48 h) reduces the expression levels of calcineurin pathway genes cnaA and crzA in Aspergillus fumigatus Af293[3]. 2',4-Dihydroxychalcone (4-256 μg/mL; 48 h) enhances the antifungal activity of Itraconazole and Caspofungin against Aspergillus fumigatus Af293[3]. 2',4-Dihydroxychalcone (0.195-100.0 µg/mL; 72 h) potently inhibits the growth of Leishmania amazonensis promastigotes, with an IC50 of 0.4 μM, and this compound shows high selectivity for parasites over mammalian cells[4]. 2',4-Dihydroxychalcone (24 h) exhibits low cytotoxicity against mouse peritoneal macrophages, with a CC50 of 416.7 μM[4]. 2',4-Dihydroxychalcone (5-20 μg/mL; 48 h) induces morphological changes associated with apoptosis in human gastric cancer MGC-803 cells, with severe cell detachment and nuclear damage observed at the highest concentration[5]. 2',4-Dihydroxychalcone (5-20 μg/mL; 48 h) induces cell cycle arrest in human gastric cancer MGC-803 cells: it triggers S-phase arrest at 5 μg/mL, induces G2/M-phase arrest in a dose-dependent manner as the concentration increases to 10 μg/mL, while the G2/M-phase arrest effect attenuates at 20 μg/mL[5]. 2',4-Dihydroxychalcone (2.5-20 μg/mL; 48 h) increases the activity of caspase-3 in human gastric cancer MGC-803 cells in a dose-dependent manner[5]. 2',4-Dihydroxychalcone (5-20 μg/mL; 48 h) downregulates the expression of survivin mRNA in human gastric cancer MGC-803 cells in a dose-dependent manner[5]. 2',4-Dihydroxychalcone (0.2-5 μM; cultured to an OD600 of 1.8-2.0) potently reduces the transcription levels of HlyU-regulated toxin genes rtxA1 and vvhA in wild-type Vibrio vulnificus MO6-24/O, without altering the expression of hlyU or hns[6]. 2',4-Dihydroxychalcone (2-8 μM) inhibits the hemolytic activity of wild-type *Vibrio vulnificus* MO6-24/O in a concentration-dependent manner, and at the concentration of 8 μM, the hemolysis level decreases to a level comparable to that of the ΔhlyU mutant[6]. 2',4-Dihydroxychalcone exhibits low cytotoxicity against HeLa and HEK293 cells, with IC50 values of 100.3 μM and 60.0 μM, respectively, which are much higher than the maximum working concentration of 8 μM[6]. 2',4-Dihydroxychalcone (150-300 μM) inhibits the specific DNA-binding activity of purified wild-type Vibrio vulnificus HlyU protein with the PrtxA1 promoter, and prevents the formation of specific high-mobility DNA-protein complexes[6].
References:
[1]. Zhang G, et al. 2',4'-dihydroxychalcone alleviates inflammatory bowel disease by inhibiting NLRP3 inflammasome and modulating gut microbiota. Frontiers in immunology. 2026;17:1751218.
[2]. Wang T, et al. 2',4'-dihydroxychalcone induces ferroptosis through ERO1A/GPX4 regulatory axis in cholangiocarcinoma. Phytomedicine: international journal of phytotherapy and phytopharmacology. 2025 Nov;147:157192.
[3]. Seo YH, et al. In Vitro Antifungal Activity and Mode of Action of 2',4'-Dihydroxychalcone against Aspergillus fumigatus. Mycobiology. 2015 Jun;43(2):150-6.
[4]. Passalacqua TG, et al. The 2',4'-dihydroxychalcone could be explored to develop new inhibitors against the glycerol-3-phosphate dehydrogenase from Leishmania species. Bioorganic & medicinal chemistry letters. 2015 Sep 01;25(17):3564-8.
[5]. Lou C, et al. 2',4'-Dihydroxychalcone-induced apoptosis of human gastric cancer MGC-803 cells via down-regulation of survivin mRNA. Toxicology in vitro: an international journal published in association with BIBRA. 2010 Aug;24(5):1333-7.
[6]. Imdad S, et al. Identification of 2',4'-Dihydroxychalcone as an Antivirulence Agent Targeting HlyU, a Master Virulence Regulator in Vibrio vulnificus. Molecules. 2018 Jun 20;23(6):1492.
In Vivo, 2',4-Dihydroxychalcone (10-30 mg/kg; i.g.; daily; 10 days) significantly alleviates DSS -induced acute ulcerative colitis in C57BL/6J mice by inhibiting NLRP3 inflammasome activation, restoring gut barrier integrity, and balancing gut microbiota, with no observed organ toxicity[1]. 2',4-Dihydroxychalcone (6.25-12.5 mg/kg; i.p.; repeated dosing schedule) significantly inhibits cholangiocarcinoma xenograft tumor growth with minimal organ toxicity[2]. 2',4-Dihydroxychalcone (15 mg/kg; injection; single dose) provides ~50% protection to Galleria mellonella larvae against Vibrio vulnificus infection[6].
In Vitro, 2',4-Dihydroxychalcone (1.25-40 μM; 1-2 h) selectively inhibits NLRP3 inflammasome activation in THP-1-derived macrophages and 774A.1 macrophages by blocking the cleavage of caspase-1 and Gasdermin D, and exhibits no cytotoxicity at concentrations up to 40 μM[1]. 2',4-Dihydroxychalcone (25 μM; 1 h) potently inhibits Nigericin -induced IL-1β secretion in THP-1-derived macrophages[1]. 2',4-Dihydroxychalcone (12.5-50 µM; 24-72 h) potently inhibits the proliferation of HuCCT1 and QBC939 cholangiocarcinoma cells in a concentration-dependent manner[2]. 2',4-Dihydroxychalcone (12.5-50 µM; 14 days) inhibits the colony-forming ability of HuCCT1 and QBC939 cholangiocarcinoma cells in a concentration-dependent manner[2]. 2',4-Dihydroxychalcone (25 µM; 24 h) inhibits the proliferation of HuCCT1 and QBC939 cholangiocarcinoma cells by reducing EdU incorporation[2]. 2',4-Dihydroxychalcone (12.5-50 µM; 48 h) inhibits horizontal and vertical migration of HuCCT1 and QBC939 cholangiocarcinoma cells in a concentration-dependent manner[2]. 2',4-Dihydroxychalcone (12.5-50 µM; 24 h) increases intracellular ROS levels in HuCCT1 and QBC939 cholangiocarcinoma cells in a concentration-dependent manner[2]. 2',4-Dihydroxychalcone (12.5-50 µM; 24 h) induces ferroptosis in HuCCT1 and QBC939 cholangiocarcinoma cells[2]. 2',4-Dihydroxychalcone (12.5-50 µM; 24 h) inhibits epithelial-mesenchymal transition in HuCCT1 and QBC939 cholangiocarcinoma cells, while downregulating the PI3K/AKT/mTOR signaling pathway and ferroptosis-related markers SLC7A11 and GPX4[2]. 2',4-Dihydroxychalcone (12.5-50 µM) downregulates the expression of ERO1A in HuCCT1 and QBC939 cholangiocarcinoma cells in a concentration-dependent manner[2]. 2',4-Dihydroxychalcone (0.06-256 μg/mL; 48 h) inhibits the metabolic activity and hyphal growth of Aspergillus fumigatus Af293, with an MIC50 ranging from 64 to 128 μg/mL, and significantly reduces hyphal growth at a concentration of 256 μg/mL[3]. 2',4-Dihydroxychalcone (8 μg/mL; 48 h) inhibits the radial growth of Aspergillus fumigatus Af293 by 20%, blocks its sporulation process, and reduces the expression levels of sporulation-related genes brlA, abaA and wetA by 3-5 folds[3]. 2',4-Dihydroxychalcone (8 μg/mL; 48 h) reduces the expression levels of calcineurin pathway genes cnaA and crzA in Aspergillus fumigatus Af293[3]. 2',4-Dihydroxychalcone (4-256 μg/mL; 48 h) enhances the antifungal activity of Itraconazole and Caspofungin against Aspergillus fumigatus Af293[3]. 2',4-Dihydroxychalcone (0.195-100.0 µg/mL; 72 h) potently inhibits the growth of Leishmania amazonensis promastigotes, with an IC50 of 0.4 μM, and this compound shows high selectivity for parasites over mammalian cells[4]. 2',4-Dihydroxychalcone (24 h) exhibits low cytotoxicity against mouse peritoneal macrophages, with a CC50 of 416.7 μM[4]. 2',4-Dihydroxychalcone (5-20 μg/mL; 48 h) induces morphological changes associated with apoptosis in human gastric cancer MGC-803 cells, with severe cell detachment and nuclear damage observed at the highest concentration[5]. 2',4-Dihydroxychalcone (5-20 μg/mL; 48 h) induces cell cycle arrest in human gastric cancer MGC-803 cells: it triggers S-phase arrest at 5 μg/mL, induces G2/M-phase arrest in a dose-dependent manner as the concentration increases to 10 μg/mL, while the G2/M-phase arrest effect attenuates at 20 μg/mL[5]. 2',4-Dihydroxychalcone (2.5-20 μg/mL; 48 h) increases the activity of caspase-3 in human gastric cancer MGC-803 cells in a dose-dependent manner[5]. 2',4-Dihydroxychalcone (5-20 μg/mL; 48 h) downregulates the expression of survivin mRNA in human gastric cancer MGC-803 cells in a dose-dependent manner[5]. 2',4-Dihydroxychalcone (0.2-5 μM; cultured to an OD600 of 1.8-2.0) potently reduces the transcription levels of HlyU-regulated toxin genes rtxA1 and vvhA in wild-type Vibrio vulnificus MO6-24/O, without altering the expression of hlyU or hns[6]. 2',4-Dihydroxychalcone (2-8 μM) inhibits the hemolytic activity of wild-type *Vibrio vulnificus* MO6-24/O in a concentration-dependent manner, and at the concentration of 8 μM, the hemolysis level decreases to a level comparable to that of the ΔhlyU mutant[6]. 2',4-Dihydroxychalcone exhibits low cytotoxicity against HeLa and HEK293 cells, with IC50 values of 100.3 μM and 60.0 μM, respectively, which are much higher than the maximum working concentration of 8 μM[6]. 2',4-Dihydroxychalcone (150-300 μM) inhibits the specific DNA-binding activity of purified wild-type Vibrio vulnificus HlyU protein with the PrtxA1 promoter, and prevents the formation of specific high-mobility DNA-protein complexes[6].
References:
[1]. Zhang G, et al. 2',4'-dihydroxychalcone alleviates inflammatory bowel disease by inhibiting NLRP3 inflammasome and modulating gut microbiota. Frontiers in immunology. 2026;17:1751218.
[2]. Wang T, et al. 2',4'-dihydroxychalcone induces ferroptosis through ERO1A/GPX4 regulatory axis in cholangiocarcinoma. Phytomedicine: international journal of phytotherapy and phytopharmacology. 2025 Nov;147:157192.
[3]. Seo YH, et al. In Vitro Antifungal Activity and Mode of Action of 2',4'-Dihydroxychalcone against Aspergillus fumigatus. Mycobiology. 2015 Jun;43(2):150-6.
[4]. Passalacqua TG, et al. The 2',4'-dihydroxychalcone could be explored to develop new inhibitors against the glycerol-3-phosphate dehydrogenase from Leishmania species. Bioorganic & medicinal chemistry letters. 2015 Sep 01;25(17):3564-8.
[5]. Lou C, et al. 2',4'-Dihydroxychalcone-induced apoptosis of human gastric cancer MGC-803 cells via down-regulation of survivin mRNA. Toxicology in vitro: an international journal published in association with BIBRA. 2010 Aug;24(5):1333-7.
[6]. Imdad S, et al. Identification of 2',4'-Dihydroxychalcone as an Antivirulence Agent Targeting HlyU, a Master Virulence Regulator in Vibrio vulnificus. Molecules. 2018 Jun 20;23(6):1492.
| Cas No. | 13323-66-5 | SDF | |
| Formula | C15H12O3 | M.Wt | 240.25 |
| Solubility | DMSO: 100 mg/mL (416.23 mM; Need ultrasonic) | Storage | Store at 4°C, stored under nitrogen |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 4.1623 mL | 20.8117 mL | 41.6233 mL |
| 5 mM | 832.5 μL | 4.1623 mL | 8.3247 mL |
| 10 mM | 416.2 μL | 2.0812 mL | 4.1623 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
mg/kg
g
μL
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
% DMSO
%
% Tween 80
% saline
%DMSO
%
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Review for 2',4-Dihydroxychalcone
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)